NCT07530458Not yet recruiting
Retinoblastoma Consolidation in Egyptians
Retinoblastoma Consolidation: A Retrospective Multivariate Analysis In Egyptian Population
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
This analysis will evaluate the investigators' institution's specific experience using Ru-106 isotopes, cryotherapy, or transpupillary thermotherapy (TTT) to treat persistent or recurrent RB in patients who previously underwent systemic IVC or IAC. The investigators aim to detail the demographics, clinical indications, success rates-specifically local control and globe salvage-, predictive factors for success, and complications of each modality of treatment within a tertiary eye care setting in Egypt.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 3 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07530458
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 May 2026 to the primary completion date, 31 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Incomplete data, extraocular or orbital RB at initial presentation, or follow-up duration under one year.
Who the study is looking for
- Patients receiving secondary consolidation therapy with at least one year of post-treatment follow-up.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.